Viscosupplementation Market By Product Type (Single-Injection, Three-Injection, Five-Injection), By Application (Knee Osteoarthritis, Hip Osteoarthritis, Others), By End-User (Hospitals, Orthopaedic Clinics, Ambulatory Surgical Centers) Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles, And Market Forecast, 2025-2035

Industry Outlook

The Viscosupplementation Market was valued at USD 4.88 Billion in 2024 and is projected to reach USD 12.85 Billion by 2035, growing at a CAGR of approximately 9.2% between 2025 and 2035. The Viscosupplementation Market is involved in therapies for osteoarthritis and depends on hyaluronic acid injections that facilitate joint lubrication, increase mobility, and relieve pain. These injections are non-surgical therapies that provide alternative options in areas where procedures are likely to occur, such as knee osteoarthritis.

The market covers all sorts of products with single or multiple injections produced by the biopharmaceutical drug and medical device industries. An aging population, an increase in osteoarthritis instances, and advancements in hyaluronic acid products are all important factors driving growth in this market.

Report Scope:

Market Dynamics

Rising prevalence of osteoarthritis across all age groups boosting demand for viscosupplementation therapies

The rising number of people suffers from osteoarthritis and the disease's increasing prevalence, regardless of age, are contributing reasons to the expansion of the viscosupplementation market. Lifestyle changes, obesity, and inactivity are all risk factors for joint degradation, so even the young are not immune. Furthermore, viscosupplementation is widely acknowledged because it is a safe therapy that relieves pain and improves joint mobility. This is an emerging trend that emphasizes the need for more permanent, non-invasive therapeutic options. As a result of this, and with ever-increasing knowledge of OA management, we anticipate that the Viscosupplementation Market will continue to grow.

Concerns regarding early identification of osteoarthritis have led to an increase in the use of viscosupplementation therapy. Doctors are recommending these treatments to assist in managing the symptoms of the disease and delaying its progression. This decision was also impacted by the cost, availability, and affordability of hyaluronic acid injections derived from natural sources. This increase in demand across various age groups highlights the versatility and efficacy of these treatments, indicating the Viscosupplementation Market's proper role in the global treatment of osteoarthritis.

Increasing geriatric population with joint degeneration problems driving market growth

The global growth of the older population has resulted in a significant increase in osteoarthritis cases, boosting the Viscosupplementation Market. Older people typically have joint degradation caused by cartilage wear and tear, necessitating the use of efficient pain management options. Viscosupplementation is a non-surgical, less invasive treatment approach that appeals to senior individuals. Therefore, this market is becoming increasingly popular among this demographic. The ability of viscosupplementation to improve the quality of life for older persons has made it a crucial component of osteoarthritis treatment.

Viscosupplementation therapies have evolved to provide tailored treatments to meet the unique demands of the aged. Healthcare professionals can personalize care using both single and multiple injection methods, resulting in higher patient satisfaction. With estimates of a considerable increase in the aging population in the next decades, the Viscosupplementation Market is well-positioned to meet the growing demand for effective osteoarthritis care. This demographic transition highlights the critical importance of viscosupplementation in reducing the global burden of joint disease. These innovations improve treatment outcomes and the quality of life for elderly individuals.

High costs of viscosupplementation treatments limiting accessibility in low-income regions

One of the most significant disadvantages of viscosupplementation therapy is its high cost, which is too expensive for patients in underdeveloped countries. Many of these treatments use novel types of hyaluronic acid, which raises production costs and drives up patient expenses. Kus While many osteoarthritis patients would prefer to avoid a surgical operation, the majority of individuals in developing countries cannot afford such therapies, restricting the utilization of this non-operative technique. In particular, insurance coverage in such areas remains minimal, and all expenditures must be borne by the patients. This financial barrier severely limits the Viscosupplementation Market's potential to develop into economically challenged regions.

Aside from pricing considerations, the Viscosupplementation Market is also hampered by limited geographical access to healthcare institutions in low-income areas. The scarcity of skilled staff and clinics offering these therapies complicates the practicality of patient care based only on budgetary considerations. It provides a significant barrier for businesses looking to develop a presence in these areas since they must minimize costs while maintaining high-quality products. Overcoming these economic and logistical constraints is critical to promoting Viscosupplementation Market growth in the identified regions.

Growing investments in research for improved viscosupplementation products with longer-lasting effects

The viscosupplementation market is observing increased attempts at research and development to come up with better products with longer therapeutic benefits. Hyaluronic acid formulations are progressively being created to increase their viscosity, resulting in improved joint lubrication and pain relief duration. There are predictions that development will lower the amount of injections required for patients while also rewarding both customers and providers of services. Furthermore, these strategies aim to minimize some of the shortcomings of present therapies, which only provide transient pain relief, and make viscosupplementation more dependable and effective. An increase in such funding is one of the primary factors influencing technological improvements as a trend in the Viscosupplementation Market.

This focus on creating better and longer-lasting viscosupplementation products is fully in tune with the increased international interest in non-surgical solutions for osteoarthritis treatment. Given emerging new products and ways of administration, firms in the Viscosupplementation Market are attaining a competitive edge by offering better product options. Many of these innovations help patients, clinicians, and healthcare systems by reducing costs related to repeated treatments. Given the upcoming pipeline of first-in-class pharmaceuticals, it is envisaged that they would increase public access to the market, particularly for geriatrics. As a result, it is necessary to prioritize research and development to realize the full potential of the viscosupplementation sector.

Expanding awareness of non-surgical osteoarthritis treatments in emerging economies

The viscosupplementation market in emerging economies is seeing a surge in demand for non-surgical osteoarthritis therapies. Healthcare experts, governments, and industry stakeholders are all working to raise awareness of the presence and efficacy of viscosupplementation, which is pushing therapy adoption. These locations frequently confront hurdles in terms of surgical availability and expense, making viscosupplementation an appealing option. Messages emphasizing its minimal invasiveness and ability to alleviate joint pain without surgery are effective in convincing patients. This growing awareness represents an evolving culture that is creating new market opportunities for viscosupplementation in developing countries.

Moreover, increased penetration of healthcare centers, combined with rising disposable income levels in various emerging regions, are propelling the Viscosupplementation Market. Government and business groups are investing in training programs to enable healthcare staff to properly administer viscosupplementation. The patronage of local distributors enables worldwide market leaders to expand into hitherto unexplored territories. Such initiatives are creating an enabling subculture for the advancement of viscosupplementation as a popular osteoarthritis treatment. Therefore, countries that demonstrate increased awareness of such a product will continue to be prospective leaders in the Viscosupplementation Market.

Industry Expert’s Opinions

"Viscosupplementation has revolutionized the management of knee osteoarthritis, providing patients with a viable alternative to surgery. Continuous innovation in hyaluronic acid formulations ensures better outcomes for patients."

• Dr. Emily Carter, Orthopaedic Surgeon

"Advancements in imaging-guided viscosupplementation techniques have significantly enhanced procedure accuracy, improving patient satisfaction and overall treatment efficacy."

• Dr. Rajesh Mehta, Medical Director of the Rehabilitation Department at Jefferson Hospital

Segment Analysis

Based on the Product Type, the Viscosupplementation Market is categorized into Single-Injection, Three-injection, and Five-Injection. Single-injection products are currently the most prominent segment in the Viscosupplementation Market. This section is popular since the technique is quick and requires one application, which appeals to people who are busy and desire a faster way. Many OA patients choose single-injection viscosupplementation because it gives reasonably decent pain relief and significantly reduces joint inflammation. It has this benefit in terms of service delivery because it is simple to use and affordable, particularly in places with strong patient health literacy and a desire for less sophisticated therapies.

Based on the Application, the Viscosupplementation Market is divided into Osteoarthritis Treatment, Knee Pain Relief, and Others. The largest segment in the Viscosupplementation Market is knee pain management, which includes osteoarthritis treatments. Knee osteoarthritis is a common illness that primarily affects the elderly; viscosupplementation has long been recognized as a conservative and safe way of pain management and joint function restoration. The primary reason for this segment's sustained growth is a shift away from surgical procedures and toward non-invasive treatments. One of the most common types of viscosupplementation is based on hyaluronic acid and is intended to provide complete lubrication of the knee joint while also reducing inflammation. The market's growth is driven by the focus on knee pain relief.

Regional Analysis

The North American Viscosupplementation Market is leading due to an advanced healthcare system, a tendency to accept novel medical treatments and goods, and a growing older population, putting it ahead of other competitors. However, the United States dominates the market due to the huge number of osteoarthritis patients and improved knowledge of non-operative treatment options. In addition to insurance and reimbursement, patients can receive viscosupplementation therapy. Furthermore, major market players and continuous research investments in industry advancement contribute to the region's dominance.

As a result, North America is likely to continue to have the highest demand for viscosupplementation. The strong infrastructure and continued adoption of advanced medical technologies also play a significant role in maintaining the region's leadership.

The Asia-Pacific Viscosupplementation Market is growing due to the continuous increase in economic development, improved access to healthcare services, and an emerging elderly population, particularly in Japan, China, and India. However, awareness of treatment forms is on the rise, and one of the forms is viscosupplementation because it is non-invasive. These therapies are required by the patients, and the general demand for them continues to increase. The growing prevalence of osteoarthritis and joint-related disorders further drives the demand for viscosupplementation treatments in the region. Government initiatives and rising healthcare investments are also fostering market expansion in this region.

Competitive Landscape

The global viscosupplementation market is dominated by Sanofi, Seikagaku Corporation, Zimmer Biomet, Anika Therapeutics, Inc., Bioventus LLC, and Ferring Pharmaceuticals. These firms are aggressively driving the development of more progressive treatments for osteoarthritis and joint pain. Sanofi, for example, controls the majority of the market with its Synvisc medicines, as does Seikagaku with its Hyalgan.

Durolane by Zimmer Biomet remains as dominant as Supartz FX by Bioventus, with Monovisc and Gelsyn 3 being introduced to Anika Therapeutics' product line. Ferring just received the necessary approvals for the Hyalgan works, demonstrating the market's competitiveness. They are increasing their investment in R&D to develop better and longer-lasting viscosupplementation, which will improve the market.

Viscosupplementation Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In May 2024, LG Chem expanded its viscosupplementation portfolio with a new product for hip OA.
• In April 2024, Zimmer Biomet announced FDA approval for a single injection viscosupplementation device, improving patient convenience.
• In March 2024, Anika Therapeutics launched a next-generation hyaluronic acid formulation for extended efficacy in knee OA treatment.
• In November 2022, Anika Therapeutics Inc. completed a phase-3 clinical trial focused on a single primary endpoint. The medication was designed for individuals with severe knee osteoarthritis, and the company focused on obtaining FDA approval and clearance for use in the global market.

Report Coverage:

By Product Type

• Single-Injection
• Three-Injection
• Five-Injection

By Application

• Osteoarthritis Treatment
• Knee Pain Relief
• Others

By End-User

• Hospitals
• Orthopedic Clinics
• Ambulatory Surgery Centres

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Sanofi
• Seikagaku Corporation
• Zimmer Biomet
• Anika Therapeutics, Inc.
• Bioventus LLC
• Ferring Pharmaceuticals
• LG Chem
• Lifecore Biomedical LLC
• OrthogenRx, Inc.
• Medline Industries, Inc.
• Smith & Nephew plc
• Croma-Pharma GmbH
• Chugai Pharmaceutical Co., Ltd.
• Shandong Freda Biochem Co., Ltd.
• C. C. Medico Ltd.
• BioPolymer GmbH & Co. KG
• Maruha Nichiro Corporation

Frequently Asked Questions (FAQs)